Photocure ASA · OSL:PHO
Photocure ASA — J.P. Morgan – BioNJ Eighth Annual Bio-Partnering Conference 2018
13 slides from Photocure ASA's conference presentation, May 3, 2018
Slide 1: Photocure
PHOTOCURE MAY 2018 Ambaw Bellete, President, Photocure Inc.
Slide 2: Disclaimer
DISCLAIMER The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Photocure ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These statements are based on various as
Slide 3: Photocure at a Glance
OSLO (HQ) PHOTOCURE AT A GLANCE PRINCETON, NJ 70 Norwegian commercial-stage company NORWAY focused on bladder cancer. SWEDEN DENMARK Own commercial operations in Nordics EMPLOYEES FINLAND and USA. Partners in Europe, Canada, U.S.A. Australia and New Zealand. 20 CORE PRODUCT ON MARKET: REVENUES US $
Slide 4: Large Unmet Needs in Non-Muscle Invasive Bladder Cancer (NMIBC)
LARGE UNMET NEEDS IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) COMMON RECURRING 9th most common cancer worldwide 61% recurrence in 1 year 430 000 78% new cases recurrence in 5 years 165 000 DEBILITATING EXPENSIVE Lifelong follow-up 1 deaths annually with repeat TURBTs # Highest per patient lifetime
Slide 5: Strategic Focus on Expanding Bladder Cancer Offerings
STRATEGIC FOCUS ON EXPANDING BLADDER CANCER OFFERINGS CORE PRODUCT ON MARKET: NEW CORE PRODUCTS: NON-CORE PIPELINE PRODUCTS: Complementary, Visonac® (Acne treatment) within bladder cancer Cevira® (Cervical disease treatment) Bladder cancer detection & management Focus next Growth in existing markets
Slide 6: Blue Light Cystoscopy with Hexvix/Cysview
BLUE LIGHT CYSTOSCOPY WITH HEXVIX®/CYSVIEW® CONFIDENCE AT FIRST SIGHT • Detect STANDARD WHITE BLC™ WITH HEXVIX/CYSVIEW – improves detection of bladder lesions and the LIGHT accuracy of diagnosis right from the start • Treat – ensures more complete removal of bladder tumors, reduced recurrence risk,
Slide 7: BLC with Cysview Inclusion in National Guidelines
BLC WITH CYSVIEW INCLUSION IN NATIONAL GUIDELINES Transforming Clinical Practice • US Guidelines: Use of Blue Light Cystoscopy with Hexvix/Cysview receives highest level of recommendation in the new AUA/SUO bladder cancer guideline ─ Recommended based on the large body of evidence supporting both in
Slide 8: Expanded US Market Opportunity Through Supplemental New Drug Approval
EXPANDED US MARKET OPPORTUNITY THROUGH SUPPLEMENTAL NEW DRUG APPROVAL • February 2018 obtained US FDA approval of an extension of the Cysview indication • Blue Light Cystoscopy (BLC) with Cysview indicated to be used in bladder cancer patients undergoing surveillance cystoscopy for bladder cancer •
Slide 9: Medicare Reimbursement of an Additional USD 1,000 per TURBT from 2018
MEDICARE REIMBURSEMENT OF AN ADDITIONAL USD 1,000 PER TURBT FROM 2018* Medicare (~55% of TURBT) Private payer (~45% of TURBT) • Procedure fee for cystoscopy • Procedure fee for cystoscopy • Cysview paid at contracted rate (ASP** +6 to Cystoscopy • Cysview paid at ASP** +6% 15%) • No change from 2017
Slide 10: Hexvix/Cysview Significant Growth Opportunity with New US Label
HEXVIX/CYSVIEW SIGNIFICANT GROWTH OPPORTUNITY WITH NEW US LABEL BLC with Total Number Number of Market Peak sales value with Peak sales value with Peak sales value with Cysview of Cystoscopy Procedures potential in 5% market share in 10% market share in 20% market share in top Market Procedures in t
Slide 11: Delivering on Key 2017 Objectives
DELIVERING ON KEY 2017 OBJECTIVES • US sales revenue up 27% YoY in 4Q and 39% FY, driven by in-market volume increase in 4Q of 21% and 31% FY Increase growth of Cysview® in US based • New increased CMS reimbursement for Blue Light Cystoscopy (BLC™) with on increased investment in US Cysview for use
Slide 12: Focus & Objectives 2018
FOCUS & OBJECTIVES 2018 • Continue investment in the US operations to increase Cysview revenues and achieve 2020 revenue target Increase growth of Cysview® in US • Expand the number of hospitals with blue light enabled scopes TURBT market • Continue to increase the awareness of the medical benefits
Slide 13: Thank you for your attention
Thank you for your attention 13
Photocure — J.P. Morgan – BioNJ Eighth Annual Bio-Partnering Conference 2018 on 6ix